产品
编 号：F423696
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 677010-34-3
产品详情
生物活性：
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
体内研究：
Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice.Animal Model:Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2
Dosage:1.25 mg in 0.1 ml of PBS/per mouse
Administration:Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
Result:Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5.Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.
体外研究：
Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription.Motavizumab inhibits F protein-mediated cell-to-cell fusion.
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
体内研究：
Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice.Animal Model:Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2
Dosage:1.25 mg in 0.1 ml of PBS/per mouse
Administration:Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
Result:Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5.Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.
体外研究：
Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription.Motavizumab inhibits F protein-mediated cell-to-cell fusion.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备